Filing Analysis
Gain Therapeutics, Inc. disclosed interim clinical and biomarker data from a Phase 1b study extension for GT-02287 in Parkinson's disease patients. The data shows a significant reduction in CSF GluSph levels and positive trends in MDS-UPDRS scores, particularly for patients with high baseline GluSph.
📋 Key Facts
- Interim data from Part 2 (nine-month extension) of Phase 1b study of GT-02287 released May 26, 2026.
- 16 of 19 participants from Part 1 continued into the extension study.
- CSF GluSph levels decreased by an average of 81% after 90 days of treatment in participants with elevated baseline levels.
- Patients with high baseline GluSph showed a 4.8 point difference in MDS-UPDRS Part II and III scores compared to low baseline GluSph patients at Day 150.
- Participants reported unsolicited benefits including improved smell, taste, balance, gait, and sleep.
- A Data Monitoring Committee meeting on March 5, 2026, concluded the study should continue without changes.
Gain Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a general business update via a press release.
📋 Key Facts
- Announced Q1 2026 financial results on May 11, 2026
- Furnished press release as Exhibit 99.1
- Reported under Item 2.02 (Results of Operations and Financial Condition)
- Signed by CEO Gene Mack
Gain Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. The information was furnished via a press release as part of a routine Item 2.02 filing.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made on March 26, 2026.
- The report includes a business update in addition to financial metrics.
- The filing was signed by Gene Mack, Chief Executive Officer.
Gain Therapeutics announced positive clinical and biomarker data from its Phase 1b study of GT-02287 in Parkinson's Disease at the AD/PD 2026 conference. The data demonstrated substantial biomarker reductions and stable clinical scores over 150 days, alongside the introduction of a new IND-ready preclinical candidate.
📋 Key Facts
- 16 out of 19 participants who completed Part 1 of the Phase 1b study elected to continue into the 9-month extension (Part 2).
- A Data Monitoring Committee (DMC) meeting on March 5, 2026, recommended the study continue without changes.
- Participants with elevated baseline GluSph levels saw substantial decreases in the biomarker after 90 days of treatment.
- MDS-UPDRS scores remained stable over 150 days of dosing as of March 10, 2026.
- A 6.7-point difference in MDS-UPDRS Part II and III scores was observed between high and low baseline GluSph groups at Day 150.
- The company announced GT-04686 as a new lead chemical series ready for IND-enabling studies.